18F-FDG-PET is superior to WHO grading as prognostic tool in neuroendocrine neoplasms and useful in guiding peptide receptor radionuclide therapy: a prospective 10-year follow-up study of 166 patients

Research output: Contribution to journalJournal articlepeer-review

Standard

18F-FDG-PET is superior to WHO grading as prognostic tool in neuroendocrine neoplasms and useful in guiding peptide receptor radionuclide therapy : a prospective 10-year follow-up study of 166 patients. / Binderup, Tina; Knigge, Ulrich; Johnbeck, Camilla Bardram; Loft, Annika; Berthelsen, Anne Kiil; Oturai, Peter; Mortensen, Jann; Federspiel, Birgitte; Langer, Seppo W; Kjaer, Andreas.

In: The Journal of Nuclear Medicine, Vol. 62, No. 6, 2021, p. 808-815.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Binderup, T, Knigge, U, Johnbeck, CB, Loft, A, Berthelsen, AK, Oturai, P, Mortensen, J, Federspiel, B, Langer, SW & Kjaer, A 2021, '18F-FDG-PET is superior to WHO grading as prognostic tool in neuroendocrine neoplasms and useful in guiding peptide receptor radionuclide therapy: a prospective 10-year follow-up study of 166 patients', The Journal of Nuclear Medicine, vol. 62, no. 6, pp. 808-815. https://doi.org/10.2967/jnumed.120.244798

APA

Binderup, T., Knigge, U., Johnbeck, C. B., Loft, A., Berthelsen, A. K., Oturai, P., Mortensen, J., Federspiel, B., Langer, S. W., & Kjaer, A. (2021). 18F-FDG-PET is superior to WHO grading as prognostic tool in neuroendocrine neoplasms and useful in guiding peptide receptor radionuclide therapy: a prospective 10-year follow-up study of 166 patients. The Journal of Nuclear Medicine, 62(6), 808-815. https://doi.org/10.2967/jnumed.120.244798

Vancouver

Binderup T, Knigge U, Johnbeck CB, Loft A, Berthelsen AK, Oturai P et al. 18F-FDG-PET is superior to WHO grading as prognostic tool in neuroendocrine neoplasms and useful in guiding peptide receptor radionuclide therapy: a prospective 10-year follow-up study of 166 patients. The Journal of Nuclear Medicine. 2021;62(6):808-815. https://doi.org/10.2967/jnumed.120.244798

Author

Binderup, Tina ; Knigge, Ulrich ; Johnbeck, Camilla Bardram ; Loft, Annika ; Berthelsen, Anne Kiil ; Oturai, Peter ; Mortensen, Jann ; Federspiel, Birgitte ; Langer, Seppo W ; Kjaer, Andreas. / 18F-FDG-PET is superior to WHO grading as prognostic tool in neuroendocrine neoplasms and useful in guiding peptide receptor radionuclide therapy : a prospective 10-year follow-up study of 166 patients. In: The Journal of Nuclear Medicine. 2021 ; Vol. 62, No. 6. pp. 808-815.

Bibtex

@article{b87071f61c7644a4b65a614841d4de15,
title = "18F-FDG-PET is superior to WHO grading as prognostic tool in neuroendocrine neoplasms and useful in guiding peptide receptor radionuclide therapy: a prospective 10-year follow-up study of 166 patients",
abstract = "Accurate grading of patients with neuroendocrine neoplasms (NENs) is essential for risk stratification and optimal choice of therapy. Currently, grading is based on histologically assessed degree of tumor proliferation. The aim of the present study was to assess the long-term prognostic value of 18F-FDG-PET imaging for risk stratification of NENs and compare it with tumor grading (World Health Organization (WHO) 2010 classification). Methods: We conducted a prospective cohort study evaluating the prognostic value of 18F-FDG-PET imaging and compared it to histological grading. Enrolled were 166 patients of all grades and with histologically confirmed NENs of gastro-entero-pancreatic origin. The primary endpoint was overall survival (OS). Progression-free survival (PFS) was a secondary endpoint. In addition, OS in relation to Peptide Receptor Radionuclide Therapy (PRRT) was analyzed as an exploratory endpoint. The median follow-up time was 9.8 years. Results: Analysis of the whole cohort revealed that a positive 18F-FDG-PET was associated with a shorter OS than a negative 18F-FDG-PET (Hazard Ratio (HR): 3.8; 95% Confidence interval (CI): 2.4 - 5.9; P < 0.001). In G1 and G2 patients (n = 140) a positive 18F-FDG-PET was the only identifier of high-risk for death (HR: 3.6; 95% CI, 2.2 - 5.9; P < 0.001). In multivariate analysis, 18F-FDG-PET, G3 tumor, ≥2 liver metastases and ≥2 prior therapies were independent prognostic factors for OS and 18F-FDG-PET, G3 tumor and ≥3 liver metastases were independent prognostic factors for PFS. For patients receiving PRRT, 18F-FDG-negative cases had a significantly longer survival than the 18F-FDG-positive, whereas no difference was identified for tumor grading. 18F-FDG-positive patients receiving PRRT had a significantly longer median survival compared to patients not receiving PRRT (4.4 vs 1.4 years, P = 0.001), whereas no difference was seen for 18F-FDG-negative patients. Conclusion:18F-FDG-PET is useful for risk stratification of all NEN grades and is superior to histological grading. 18F-FDG-PET could differentiate G1 and G2 tumors into low and high-risk groups. In the selection of therapy and for risk stratification of NEN patients, 18F-FDG-PET status should be considered.",
author = "Tina Binderup and Ulrich Knigge and Johnbeck, {Camilla Bardram} and Annika Loft and Berthelsen, {Anne Kiil} and Peter Oturai and Jann Mortensen and Birgitte Federspiel and Langer, {Seppo W} and Andreas Kjaer",
note = "Copyright {\textcopyright} 2020 by the Society of Nuclear Medicine and Molecular Imaging, Inc.",
year = "2021",
doi = "10.2967/jnumed.120.244798",
language = "English",
volume = "62",
pages = "808--815",
journal = "The Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine",
number = "6",

}

RIS

TY - JOUR

T1 - 18F-FDG-PET is superior to WHO grading as prognostic tool in neuroendocrine neoplasms and useful in guiding peptide receptor radionuclide therapy

T2 - a prospective 10-year follow-up study of 166 patients

AU - Binderup, Tina

AU - Knigge, Ulrich

AU - Johnbeck, Camilla Bardram

AU - Loft, Annika

AU - Berthelsen, Anne Kiil

AU - Oturai, Peter

AU - Mortensen, Jann

AU - Federspiel, Birgitte

AU - Langer, Seppo W

AU - Kjaer, Andreas

N1 - Copyright © 2020 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

PY - 2021

Y1 - 2021

N2 - Accurate grading of patients with neuroendocrine neoplasms (NENs) is essential for risk stratification and optimal choice of therapy. Currently, grading is based on histologically assessed degree of tumor proliferation. The aim of the present study was to assess the long-term prognostic value of 18F-FDG-PET imaging for risk stratification of NENs and compare it with tumor grading (World Health Organization (WHO) 2010 classification). Methods: We conducted a prospective cohort study evaluating the prognostic value of 18F-FDG-PET imaging and compared it to histological grading. Enrolled were 166 patients of all grades and with histologically confirmed NENs of gastro-entero-pancreatic origin. The primary endpoint was overall survival (OS). Progression-free survival (PFS) was a secondary endpoint. In addition, OS in relation to Peptide Receptor Radionuclide Therapy (PRRT) was analyzed as an exploratory endpoint. The median follow-up time was 9.8 years. Results: Analysis of the whole cohort revealed that a positive 18F-FDG-PET was associated with a shorter OS than a negative 18F-FDG-PET (Hazard Ratio (HR): 3.8; 95% Confidence interval (CI): 2.4 - 5.9; P < 0.001). In G1 and G2 patients (n = 140) a positive 18F-FDG-PET was the only identifier of high-risk for death (HR: 3.6; 95% CI, 2.2 - 5.9; P < 0.001). In multivariate analysis, 18F-FDG-PET, G3 tumor, ≥2 liver metastases and ≥2 prior therapies were independent prognostic factors for OS and 18F-FDG-PET, G3 tumor and ≥3 liver metastases were independent prognostic factors for PFS. For patients receiving PRRT, 18F-FDG-negative cases had a significantly longer survival than the 18F-FDG-positive, whereas no difference was identified for tumor grading. 18F-FDG-positive patients receiving PRRT had a significantly longer median survival compared to patients not receiving PRRT (4.4 vs 1.4 years, P = 0.001), whereas no difference was seen for 18F-FDG-negative patients. Conclusion:18F-FDG-PET is useful for risk stratification of all NEN grades and is superior to histological grading. 18F-FDG-PET could differentiate G1 and G2 tumors into low and high-risk groups. In the selection of therapy and for risk stratification of NEN patients, 18F-FDG-PET status should be considered.

AB - Accurate grading of patients with neuroendocrine neoplasms (NENs) is essential for risk stratification and optimal choice of therapy. Currently, grading is based on histologically assessed degree of tumor proliferation. The aim of the present study was to assess the long-term prognostic value of 18F-FDG-PET imaging for risk stratification of NENs and compare it with tumor grading (World Health Organization (WHO) 2010 classification). Methods: We conducted a prospective cohort study evaluating the prognostic value of 18F-FDG-PET imaging and compared it to histological grading. Enrolled were 166 patients of all grades and with histologically confirmed NENs of gastro-entero-pancreatic origin. The primary endpoint was overall survival (OS). Progression-free survival (PFS) was a secondary endpoint. In addition, OS in relation to Peptide Receptor Radionuclide Therapy (PRRT) was analyzed as an exploratory endpoint. The median follow-up time was 9.8 years. Results: Analysis of the whole cohort revealed that a positive 18F-FDG-PET was associated with a shorter OS than a negative 18F-FDG-PET (Hazard Ratio (HR): 3.8; 95% Confidence interval (CI): 2.4 - 5.9; P < 0.001). In G1 and G2 patients (n = 140) a positive 18F-FDG-PET was the only identifier of high-risk for death (HR: 3.6; 95% CI, 2.2 - 5.9; P < 0.001). In multivariate analysis, 18F-FDG-PET, G3 tumor, ≥2 liver metastases and ≥2 prior therapies were independent prognostic factors for OS and 18F-FDG-PET, G3 tumor and ≥3 liver metastases were independent prognostic factors for PFS. For patients receiving PRRT, 18F-FDG-negative cases had a significantly longer survival than the 18F-FDG-positive, whereas no difference was identified for tumor grading. 18F-FDG-positive patients receiving PRRT had a significantly longer median survival compared to patients not receiving PRRT (4.4 vs 1.4 years, P = 0.001), whereas no difference was seen for 18F-FDG-negative patients. Conclusion:18F-FDG-PET is useful for risk stratification of all NEN grades and is superior to histological grading. 18F-FDG-PET could differentiate G1 and G2 tumors into low and high-risk groups. In the selection of therapy and for risk stratification of NEN patients, 18F-FDG-PET status should be considered.

U2 - 10.2967/jnumed.120.244798

DO - 10.2967/jnumed.120.244798

M3 - Journal article

C2 - 33067340

VL - 62

SP - 808

EP - 815

JO - The Journal of Nuclear Medicine

JF - The Journal of Nuclear Medicine

SN - 0161-5505

IS - 6

ER -

ID: 250162443